Ownership Submission
|
FORM 4
|
|
Check this box if no longer subject to Section 16, Form 4 or Form 5 obligations may continue. See Instruction 1(b).
|
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
OMB APPROVAL
|
|
OMB Number:3235-0287Expires:January 31, 2005Estimated average burden hours per response...0.5
|
|
|
1. Name and Address of Reporting Person *
|
|
Kaye Randall
|
|
2. Issuer Name and Ticker or Trading Symbol
Longboard Pharmaceuticals, Inc. [LBPH]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
_____ Director
|
_____ 10% Owner
|
|
_____ Officer (give title below)
|
_____ Other (specify below)
|
|
CMO /
|
|
|
(Last)
|
(First)
|
(Middle)
|
|
4275 EXECUTIVE SQUARE , SUITE 950
|
|
3. Date of Earliest Transaction (Month/Day/Year)
|
(Street)
|
|
LA JOLLA
|
CA
|
92037
|
|
4. If Amendment, Date Original Filed(Month/Day/Year)
|
6. Individual or Join/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
|
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
|
|
1.Title of Security
|
2. Transaction Date (Month/Day/Year)
|
2A. Deemed Execution Date, if any (Month/Day/Year)
|
3. Transaction Code
|
4. Securities Acquired (A) or Disposed of (D)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
|
6. Ownership Form: Direct (D) or Indirect (I)
|
7. Nature of Indirect Beneficial Ownership
|
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
(e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
|
2. Conversion or Exercise Price of Derivative Security
|
3. Transaction Date (Month/Day/Year)
|
3A. Deemed Execution Date, if any (Month/Day/Year)
|
4. Transaction Code
|
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
|
6. Date Exercisable and Expiration Date
|
7. Title and Amount of Securities Underlying Derivative Security
|
8. Price of Derivative Security
|
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)
|
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
|
11. Nature of Indirect Beneficial Ownership
|
|
Code
|
V
|
(A)
|
(D)
|
Date Exercisable
|
Expriation Date
|
Title
|
Amount or Number of Shares
|
Reporting Owners
|
Reporting Owner Name / Address
|
Relationships
|
|
Director
|
10% Owner
|
Officer
|
Other
|
Kaye Randall
4275 EXECUTIVE SQUARE
SUITE 950
LA JOLLA, CA92037
|
|
|
CMO
|
|
Signatures
|
/s/ Andrew J. Cronauer, Attorney-In-Fact
|
2024-08-13
|
|
**Signature of Reporting Person
|
Date
|
Explanation of Responses:
|
(*)
|
If the form is filed by more than one reporting person, see Instruction 5(b)(v).
|
|
(**)
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
|
(1)
|
The amount represents restricted stock units that were granted on February 8, 2024, and reported in a Form 4 filed on February 9, 2024. The restricted stock units will vest in four equal annual installments commencing on February 8, 2025, and the shares underlying the restricted stock units will be issued upon vesting and release of the restricted stock units.
|
|
(2)
|
The transaction reported in this line item of this Form 4 was effected pursuant to a Rule 10b5-1 trading plan established by the reporting person.
|
|
(3)
|
The amount includes the 17,920 restricted stock units described in footnote 1 of this Form 4.
|
|
(4)
|
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.88 to $34.87, inclusive. The reporting person undertakes to provide Longboard Pharmaceuticals, Inc., any security holder of Longboard Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 4 and 5 to this Form 4.
|
|
(5)
|
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.88 to $35.32, inclusive.
|
|
(6)
|
The shares subject to the stock option vest and become exercisable in 48 equal monthly installments commencing March 9, 2023.
|
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient,
See Instruction 6 for procedure.Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.
